FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:382-388 August 7, 1997 Number 6 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background and Methods Osteoporosis is a recognized complication of corticosteroid therapy. Whether it can be prevented is not known. We conducted a 12-month, randomized, placebo-controlled study of intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 mg per day for 76 days), given for four cycles, in 141 men and women (age, 19 to 87 years) who had recently begun high-dose corticosteroid therapy. The primary outcome measure was the difference in the change in the bone density of the lumbar spine between the groups from base line to week 52. Secondary measures included changes in the bone density of the femoral neck, trochanter, and radius and the rate of new vertebral fractures.

Results The mean (±SE) bone density of the lumbar spine and trochanter in the etidronate group increased 0.61±0.54 and 1.46±0.67 percent, respectively, as compared with decreases of 3.23±0.60 and 2.74±0.66 percent, respectively, in the placebo group. The mean differences between the groups after one year were 3.72±0.88 percentage points for the lumbar spine (P = 0.02) and 4.14±0.94 percentage points for the trochanter (P = 0.02). The changes in the femoral neck and the radius were not significantly different between the groups. There was an 85 percent reduction in the proportion of postmenopausal women with new vertebral fractures in the etidronate group as compared with the placebo group (1 of 31 patients vs. 7 of 32 patients, P = 0.05), and the etidronate-treated postmenopausal women also had significantly fewer vertebral fractures per patient (P = 0.04).

Conclusions Intermittent etidronate therapy prevents the loss of vertebral and trochanteric bone in corticosteroid-treated patients.

Source Information

From the Department of Medicine, St. Joseph's Hospital, McMaster University, Hamilton, Ont. (J.D.A., W.G.B.); the Centre Hospitalier de l'Université Laval, Ste.-Foy, Que. (J.B.); Foothills Hospital, University of Calgary, Calgary, Alta. (D.H.); St. Joseph's Hospital and Victoria General Hospital, University of Western Ontario, London (A.H.); St. Michael's Hospital and Toronto General Hospital, University of Toronto, Toronto (R.J.); Vancouver General Hospital, University of British Columbia, Vancouver (D.L.K., B.L.); St. Paul's Hospital, University of Saskatchewan, Saskatoon (W.O.); Hôpital Saint-Luc, Université de Montréal, Montreal (L.-G.S.); and Montreal General Hospital, McGill University, Montreal (A.T.) — all in Canada; and Procter & Gamble Pharmaceuticals, Cincinnati (A.A.C.). Other authors were Algis Jovaisas, M.D. (Ottawa General Hospital, University of Ottawa, Ottawa, Ont.), William C. Sturtridge, M.D. (St. Michael's Hospital and Toronto General Hospital, University of Toronto, Toronto), Tassos P. Anastassiades, M.D. (St. Mary's of the Lake Hospital, Queen's University, Kingston, Ont.), John G. Hanly, M.D. (Victoria General Hospital, Dalhousie University, Halifax, N.S.), Janet E. Pope, M.D. (Victoria General Hospital, University of Western Ontario, London), and Reginald Dias, B.Sc., Zebulun D. Horowitz, M.D., and Simon Pack, Ph.D. (Procter & Gamble Pharmaceuticals, Cincinnati).

Address reprint requests to Dr. Adachi at 501–25 Charlton Ave. E., Hamilton, ON L8N 1Y2, Canada.

Full Text of this Article

Related Letters:

Management of Hepatic Encephalopathy
Plauth M., Merli M., Kondrup J., Riordan S. M., Williams R.
Extract | Full Text  
N Engl J Med 1997; 337:1921-1922, Dec 25, 1997. Correspondence

This article has been cited by other articles:

• MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., Desai, S. B., Zhou, A., Chen, S., Carter, J., Tringale, C., Valentine, D., Johnsen, B., Grossman, J. (2008). Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. ANN INTERN MED 148: 197-213 [Abstract] [Full Text]  
• Sambrook, P. N. (2007). Anabolic Therapy in Glucocorticoid-Induced Osteoporosis. NEJM 357: 2084-2086 [Full Text]  
• Kikuchi, Y., Imakiire, T., Yamada, M., Saigusa, T., Hyodo, T., Kushiyama, T., Higashi, K., Hyodo, N., Yamamoto, K., Suzuki, S., Miura, S. (2007). Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant 22: 1593-1600 [Abstract] [Full Text]  
• Khan, A. A., Hodsman, A. B., Papaioannou, A., Kendler, D., Brown, J. P., Olszynski, W. P. (2007). Management of osteoporosis in men: an update and case example. CMAJ 176: 345-348 [Abstract] [Full Text]  
• Grigg, A. P., Shuttleworth, P., Reynolds, J., Schwarer, A. P., Szer, J., Bradstock, K., Hui, C., Herrmann, R., Ebeling, P. R. (2006). Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation. J. Clin. Endocrinol. Metab. 91: 3835-3843 [Abstract] [Full Text]  
• Todhunter, C E, Sutherland-Craggs, A, Bartram, S A, Donaldson, P T, Daly, A K, Francis, R M, Mansfield, J C, Thompson, N P (2005). Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. Gut 54: 1579-1584 [Abstract] [Full Text]  
• Toukap, A N., Depresseux, G, Devogelaer, J-P, Houssiau, F A (2005). Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus 14: 517-520 [Abstract]  
• Kananen, K., Volin, L., Laitinen, K., Alfthan, H., Ruutu, T., Valimaki, M. J. (2005). Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate. J. Clin. Endocrinol. Metab. 90: 3877-3885 [Abstract] [Full Text]  
• Licata, A. A (2005). Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates. The Annals of Pharmacotherapy 39: 668-677 [Abstract] [Full Text]  
• Yee, C-S, Crabtree, N, Skan, J, Amft, N, Bowman, S, Situnayake, D, Gordon, C (2005). Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64: 111-113 [Abstract] [Full Text]  
• Di Munno, O, Mazzantini, M, Sedie, A D., Mosca, M, Bombardieri, S (2004). Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus 13: 724-730 [Abstract]  
• Haugeberg, G, Griffiths, B, Sokoll, K B, Emery, P (2004). Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis 63: 940-944 [Abstract] [Full Text]  
• Gluck, O., Colice, G. (2004). Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases. Chest 125: 1859-1876 [Abstract] [Full Text]  
• Kotloff, R.M., Ahya, V.N. (2004). Medical complications of lung transplantation. Eur Respir J 23: 334-342 [Abstract] [Full Text]  
• Adler, R. A., Hochberg, M. C. (2003). Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163: 2619-2624 [Abstract] [Full Text]  
• Coco, M., Glicklich, D., Faugere, M. C., Burris, L., Bognar, I., Durkin, P., Tellis, V., Greenstein, S., Schechner, R., Figueroa, K., McDonough, P., Wang, G., Malluche, H. (2003). Prevention of Bone Loss in Renal Transplant Recipients: A Prospective, Randomized Trial of Intravenous Pamidronate. J. Am. Soc. Nephrol. 14: 2669-2676 [Abstract] [Full Text]  
• Porter, N., Beynon, H.L., Randeva, H.S. (2003). Endocrine and reproductive manifestations of sarcoidosis. QJM 96: 553-561 [Full Text]  
• Crawford, B. A. L., Liu, P. Y., Kean, M. T., Bleasel, J. F., Handelsman, D. J. (2003). Randomized Placebo-Controlled Trial of Androgen Effects on Muscle and Bone in Men Requiring Long-Term Systemic Glucocorticoid Treatment. J. Clin. Endocrinol. Metab. 88: 3167-3176 [Abstract] [Full Text]  
• Ringe, J. D., Dorst, A., Faber, H., Ibach, K., Preuss, J. (2003). Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford) 42: 743-749 [Abstract] [Full Text]  
• Jehle, P. M. (2003). Steroid-induced osteoporosis: how can it be avoided?. Nephrol Dial Transplant 18: 861-864 [Full Text]  
• Chantler, I W, Davie, M W J, Evans, S F, Rees, J S (2003). Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 62: 350-352 [Abstract] [Full Text]  
• Brown, J. P., Josse, R. G. (2003). Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada. CMAJ 168: SF1-38 [Abstract] [Full Text]  
• Compston, J (2003). Osteoporosis in inflammatory bowel disease. Gut 52: 63-64 [Full Text]  
• Brown, J. P., Josse, R. G. (2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167: s1-34 [Abstract] [Full Text]  
• Yeap, S. S., Hosking, D. J. (2002). Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford) 41: 1088-1094 [Abstract] [Full Text]  
• Rubin, M. R., Bilezikian, J. P. (2002). The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence. J. Clin. Endocrinol. Metab. 87: 4033-4041 [Full Text]  
• Mushtaq, T, Ahmed, S F (2002). The impact of corticosteroids on growth and bone health. Arch. Dis. Child. 87: 93-96 [Full Text]  
• Loddenkemper, K, Perka, C, Burmester, G-R, Buttgereit, F (2002). Coincidence of asymptomatic avascular necrosis and fracture of the femoral neck: a rare combination of glucocorticoid induced side effects. Ann Rheum Dis 61: 665-666 [Full Text]  
• de Sevaux, R. G. L., Hoitsma, A. J., Corstens, F. H. M., Wetzels, J. F. M. (2002). Treatment with Vitamin D and Calcium Reduces Bone Loss after Renal Transplantation: A Randomized Study. J. Am. Soc. Nephrol. 13: 1608-1614 [Abstract] [Full Text]  
• Hart, S R, Green, B (2002). Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad. Med. J. 78: 242-243 [Abstract] [Full Text]  
• Biskobing, D. M. (2002). COPD and Osteoporosis. Chest 121: 609-620 [Abstract] [Full Text]  
• Gudbjornsson, B, Juliusson, U I, Gudjonsson, F V (2002). Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61: 32-36 [Abstract] [Full Text]  
• Canalis, E., Giustina, A. (2001). Glucocorticoid-Induced Osteoporosis: Summary of a Workshop. J. Clin. Endocrinol. Metab. 86: 5681-5685 [Full Text]  
• Mehler, P. S. (2001). Regional Osteoporosis in Anorexia Nervosa. ANN INTERN MED 135: 843-844 [Full Text]  
• Karcic, E., Karcic, A. A., Naganathan, V., Sambrook, P. (2001). Osteoporosis and Fracture Risk Prevention in Long-term Glucocorticoid Therapy. Arch Intern Med 161: 1780-1781 [Full Text]  
• GROTZ, W., NAGEL, C., POESCHEL, D., CYBULLA, M., PETERSEN, K.-G., UHL, M., STREY, C., KIRSTE, G., OLSCHEWSKI, M., REICHELT, A., RUMP, L. C. (2001). Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation. J. Am. Soc. Nephrol. 12: 1530-1537 [Abstract] [Full Text]  
• Strauss, A. J., Su, J. T., Dalton, V. M. K., Gelber, R. D., Sallan, S. E., Silverman, L. B. (2001). Bony Morbidity in Children Treated for Acute Lymphoblastic Leukemia. JCO 19: 3066-3072 [Abstract] [Full Text]  
• Haddy, T. B., Mosher, R. B., Reaman, G. H. (2001). Osteoporosis in Survivors of Acute Lymphoblastic Leukemia. The Oncologist 6: 278-285 [Abstract] [Full Text]  
• Yood, R. A., Harrold, L. R., Fish, L., Cernieux, J., Emani, S., Conboy, E., Gurwitz, J. H. (2001). Prevention of Glucocorticoid-Induced Osteoporosis: Experience in a Managed Care Setting. Arch Intern Med 161: 1322-1327 [Abstract] [Full Text]  
• Yosipovitch, G., Hoon, T. S., Leok, G. C. (2001). Suggested Rationale for Prevention and Treatment of Glucocorticoid-Induced Bone Loss in Dermatologic Patients. Arch Dermatol 137: 477-481 [Abstract] [Full Text]  
• Reid, I. R. (2001). Time to End Steroid-Induced Fractures. Arch Dermatol 137: 493-494 [Full Text]  
• Rosen, C. J., Bilezikian, J. P. (2001). Anabolic Therapy for Osteoporosis. J. Clin. Endocrinol. Metab. 86: 957-964 [Abstract] [Full Text]  
• Sen, D, Keen, R W (2001). Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus 10: 227-232 [Abstract]  
• Puttick, M. P.E. (2001). Rheumatology: 11. Evaluation of the patient with pain all over. CMAJ 164: 223-227 [Full Text]  
• Naganathan, V., Jones, G., Nash, P., Nicholson, G., Eisman, J., Sambrook, P. N. (2000). Vertebral Fracture Risk With Long-term Corticosteroid Therapy: Prevalence and Relation to Age, Bone Density, and Corticosteroid Use. Arch Intern Med 160: 2917-2922 [Abstract] [Full Text]  
• Kaufman, J M, Johnell, O, Abadie, E, Adami, S, Audran, M, Avouac, B, Sedrine, W B., Calvo, G, Devogelaer, J P, Fuchs, V, Kreutz, G, Nilsson, P, Pols, H, Ringe, J, Van Haelst, L, Reginster, J Y (2000). Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 59: 765-772 [Abstract] [Full Text]  
• Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., Vandormael, K., Lombardi, A. (2000). Alendronate for the Treatment of Osteoporosis in Men. NEJM 343: 604-610 [Abstract] [Full Text]  
• Lone, A. A. (2000). Respiratory Disorders of the Elderly. Journal of Pharmacy Practice 13: 297-307 [Abstract]  
• Shaw, N J, Boivin, C M, Crabtree, N J (2000). Intravenous pamidronate in juvenile osteoporosis. Arch. Dis. Child. 83: 143-145 [Abstract] [Full Text]  
• Conron, M., Young, C., Beynon, H. L. C. (2000). Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford) 39: 707-713 [Abstract] [Full Text]  
• LLOYD, M E, SPECTOR, T D, HOWARD, R (2000). Osteoporosis in neurological disorders. J. Neurol. Neurosurg. Psychiatry 68: 543-547 [Full Text]  
• Kaminski, H. J., Daroff, R. B. (2000). Treatment of Ocular Myasthenia: Steroids Only When Compelled. Arch Neurol 57: 752-753 [Full Text]  
• Struijs, A., Smals, A., de Witte, S. A., Hackeng, W. H. L., Mulder, H. (2000). Acute effects of etidronate on glucocorticoid-induced bone degradation. Rheumatology (Oxford) 39: 523-529 [Abstract] [Full Text]  
• Pfeilschifter, J., Diel, I. J. (2000). Osteoporosis Due to Cancer Treatment: Pathogenesis and Management. JCO 18: 1570-1593 [Abstract] [Full Text]  
• Spira, A., Gutierrez, C., Chaparro, C., Hutcheon, M. A., Chan, C. K.N. (2000). Osteoporosis and Lung Transplantation: A Prospective Study. Chest 117: 476-481 [Abstract] [Full Text]  
• Wernick, R., Campbell, S. M. (2000). Update in Rheumatology. ANN INTERN MED 132: 125-133 [Full Text]  
• Scott, E M, Gaywood, I, Scott, B B (2000). Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. Gut 46: I1-8 [Full Text]  
• Goldstein, M. F., Fallon, J. J. Jr, Harning, R. (1999). Chronic Glucocorticoid Therapy-Induced Osteoporosis in Patients With Obstructive Lung Disease*. Chest 116: 1733-1749 [Abstract] [Full Text]  
• Kung, A. W. C., Chan, T. M., Lau, C. S., Wong, R. W. S., Yeung, S. S. C. (1999). Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology (Oxford) 38: 1239-1244 [Abstract] [Full Text]  
• Srivastava, T., Alon, U. S. (1999). Bisphosphonates: From Grandparents to Grandchildren. CLIN PEDIATR 38: 687-702 [Abstract]  
• Reid, I. R. (1999). Glucocorticoid Osteoporosis: Reid IR Glucocorticoid osteoporosis J Intensive Care Med 1999, 14231-242. J Intensive Care Med 14: 231-242  
• Mehler, P. S., Bravender, T., Becker, A. E., Grinspoon, S. K., Klibanski, A., Herzog, D. B. (1999). Eating Disorders. NEJM 341: 614-616 [Full Text]  
• Mitchell, D. M, Woodcock, A. (1999). Introduction. Thorax 54: S1-1  
• COMPSTON, J E (1999). Management of bone disease in patients on long term glucocorticoid therapy. Gut 44: 770-772 [Full Text]  
• COMPSTON, J E (1999). . Gut 44: 780-781 [Full Text]  
• Lips, P. (1999). Prevention of corticosteroid induced osteoporosis. BMJ 318: 1366-1367 [Full Text]  
• Millson, D., Clark, W., Dewulf, L., Batterbury, M (1999). Standards in advertising. BMJ 318: 330-330 [Full Text]  
• Heaney, R. P. (1998). Bone Mass, Bone Fragility, and the Decision to Treat. JAMA 280: 2119-2120 [Full Text]  
• Geusens, P., Dequeker, J., Vanhoof, J., Stalmans, R., Boonen, S., Joly, J., Nijs, J., Raus, J. (1998). Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis 57: 724-727 [Abstract] [Full Text]  
• Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., Czachur, M., Daifotis, A. G., Lane, N., Correa-Rotter, R., Yanover, M., Westhovens, R., Epstein, S., Adachi, J. D., Poubelle, P., Melo-Gomes, J., Rodriguez-Portales, J. A., The Glucocorticoid-Induced Osteoporosis Interventi, (1998). Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. NEJM 339: 292-299 [Abstract] [Full Text]  
• Reid, I. R. (1998). Glucocorticoid Effects on Bone. J. Clin. Endocrinol. Metab. 83: 1860-1862 [Full Text]  
• (1998). Managing the Risks of Corticosteroid Therapy. Journal Watch Dermatology 1998: 11-11 [Full Text]  
• COWAN, S., MORIN, S., ERNST, P. (1998). Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases. Thorax 53: 331-332 [Full Text]  
• Rizzato, G. (1998). Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 53: 425-429 [Full Text]  
• Roux, C., Oriente, P., Laan, R., Hughes, R. A., Ittner, J., Goemaere, S., Di Munno, O., Pouillès, J. M., Horlait, S., Cortet, B. (1998). Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss. J. Clin. Endocrinol. Metab. 83: 1128-1133 [Abstract] [Full Text]  
• Disla, E., Tamayo, B., Fahmy, A., Adachi, J. D., Pack, S., Chines, A. A. (1997). Intermittent Etidronate and Corticosteroid-Induced Osteoporosis. NEJM 337: 1921-1921 [Full Text]  
• Kleerekoper, M., Schiebinger, R., Gutai, J. P. (1997). Steroid Therapy for Adrenal Disorders--Getting the Dose Right. J. Clin. Endocrinol. Metab. 82: 3923-3925 [Full Text]  
• (1997). Etidronate for Steroid-Induced Osteoporosis. Journal Watch Dermatology 1997: 19-19 [Full Text]  
• (1997). ETIDRONATE FOR STEROID-INDUCED OSTEOPOROSIS. JWatch General 1997: 3-3 [Full Text]  
• Reid, I. R. (1997). Preventing Glucocorticoid-Induced Osteoporosis. NEJM 337: 419-421 [Full Text]  
• SOCIETY, B. T., COMMITTEE, S. O. C. (1990). The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations. Thorax 54: 1S-28 [Full Text]